Last reviewed · How we verify
Solifenacin for 12 weeks
At a glance
| Generic name | Solifenacin for 12 weeks |
|---|---|
| Also known as | Vesicare |
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women (PHASE4)
- Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study (PHASE4)
- Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy
- Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry) (PHASE3)
- Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder (NA)
- Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (PHASE3)
- Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. (PHASE4)
- A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |